TRVI Stock Price, Trevi Therapeutics Inc Quote, Chart

Market Summary

USD2.76-0.08

Delayed

-2.82%

TRVI Stock Price

View Fullscreen

TRVI RSI Chart

TRVI Valuation

Market Cap

194.4M

Price/Earnings (Trailing)

-5.79

EV/EBITDA

-5.42

Price/Free Cashflow

-5.7

MarketCap/EBT

-5.79

TRVI Price/Sales (Trailing)

TRVI Profitability

Return on Equity

-46.4%

Return on Assets

-42.73%

Free Cashflow Yield

-17.55%

TRVI Fundamentals

TRVI Earnings

Earnings (TTM)

-33.6M

Earnings Growth (Yr)

-70.32%

Earnings Growth (Qtr)

-39.39%

Breaking Down TRVI Revenue

Last 7 days

1.1%

Last 30 days

7.0%

Last 90 days

1.1%

Trailing 12 Months

17.5%

How does TRVI drawdown profile look like?

TRVI Financial Health

Current Ratio

14.55

TRVI Investor Care

Shares Dilution (1Y)

17.26%

Diluted EPS (TTM)

-0.34

Tracking the Latest Insider Buys and Sells of Trevi Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 11, 2023	delfini lisa	sold	-1,585	2.02	-785	chief financial officer
Oct 11, 2023	delfini lisa	acquired	1,171	0.511	2,292	chief financial officer
Sep 11, 2023	delfini lisa	sold	-1,564	2.2	-711	chief financial officer
Sep 11, 2023	delfini lisa	acquired	1,170	0.511	2,291	chief financial officer
Aug 11, 2023	delfini lisa	sold	-1,609	2.36	-682	chief financial officer
Aug 11, 2023	delfini lisa	acquired	1,171	0.511	2,292	chief financial officer
Jul 11, 2023	delfini lisa	acquired	1,171	0.511	2,292	chief financial officer
Jul 11, 2023	delfini lisa	sold	-1,607	2.34	-687	chief financial officer
Jun 20, 2023	simon farrell	acquired	3,193	0.511	6,250	chief commercial officer
Jun 12, 2023	delfini lisa	sold	-1,610	2.64	-610	chief financial officer

Which funds bought or sold TRVI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-74.08	-29,403	58,974	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.93	5,321	14,618	-%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	new	-	47,000	47,000	-%
May 15, 2024	Opaleye Management Inc.	added	4.34	5,728,350	9,125,250	2.09%
May 15, 2024	VR Adviser, LLC	added	0.01	7,222,220	11,808,200	0.56%
May 15, 2024	SILVERARC CAPITAL MANAGEMENT, LLC	reduced	-2.27	1,755,010	2,912,610	0.81%
May 15, 2024	Frazier Life Sciences Management, L.P.	unchanged	-	15,574,100	25,464,800	1.07%
May 15, 2024	MPM BIOIMPACT LLC	new	-	4,626,310	4,626,310	0.74%
May 15, 2024	Checkpoint Capital L.P.	reduced	-60.84	14,280	1,745,980	1.17%
May 15, 2024	BARCLAYS PLC	reduced	-44.83	36,000	122,000	-%

Are Funds Buying or Selling TRVI?

Are funds buying TRVI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TRVI

No. of Funds

Unveiling Trevi Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 25, 2024	rosalind advisors, inc.	1.34%	926,016	SC 13G/A
Feb 14, 2024	venrock healthcare capital partners ii, l.p.	9.99%	6,707,564	SC 13G/A
Feb 14, 2024	fairmount funds management llc	0.0%	0	SC 13G/A
Feb 14, 2024	viking global investors lp	9.99%	6,599,062	SC 13G/A
Feb 12, 2024	rubric capital management lp	8.90%	5,684,420	SC 13G/A
Feb 15, 2023	rosalind advisors, inc.	4.2%	2,499,993	SC 13G
Feb 14, 2023	armistice capital, llc	4.99%	3,147,200	SC 13G/A
Feb 14, 2023	venrock healthcare capital partners ii, l.p.	9.99%	6,312,192	SC 13G/A
Feb 14, 2023	fairmount funds management llc	9.9%	6,018,465	SC 13G/A
Feb 14, 2023	viking global investors lp	9.99%	6,162,362	SC 13G/A

Recent SEC filings of Trevi Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	4	Insider Trading
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 25, 2024	SC 13G/A	Major Ownership Report
Mar 20, 2024	S-8	Employee Benefits Plan
Mar 20, 2024	10-K	Annual Report
Mar 20, 2024	8-K	Current Report

Peers (Alternatives to Trevi Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Trevi Therapeutics Inc News

Latest updates

Trevi Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-12.1%	79.00	89.00	96.00	101	116	123	128	81.00	30.00	38.00	32.00	39.00	43.00	47.00	56.00	47.00	54.00	60.00	66.00	75.00	17.00
Current Assets	-12.3%	77.00	88.00	94.00	99.00	114	123	127	80.00	30.00	38.00	31.00	38.00	42.00	46.00	55.00	46.00	54.00	60.00	66.00	75.00	15.00
Cash Equivalents	-57.4%	14.00	32.00	26.00	14.00	12.00	13.00	67.00	25.00	29.00	37.00	29.00	36.00	42.00	45.00	53.00	44.00	53.00	57.00	64.00	71.00	13.00
Net PPE	-5.6%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-9.2%	6.00	7.00	6.00	6.00	14.00	16.00	18.00	21.00	20.00	21.00	20.00	21.00	19.00	20.00	-	-	-	-	-	-	-
Current Liabilities	-9.4%	5.00	6.00	5.00	5.00	13.00	13.00	15.00	15.00	13.00	13.00	10.00	9.00	5.00	6.00	6.00	7.00	7.00	5.00	5.00	7.00	4.00
Shareholder's Equity	-12.4%	72.00	83.00	90.00	95.00	102	107	110	61.00	10.00	17.00	11.00	18.00	24.00	27.00	36.00	40.00	47.00	55.00	61.00	68.00	-
Retained Earnings	-4.6%	-250	-239	-231	-223	-216	-210	-204	-196	-188	-180	-172	-165	-155	-146	-137	-130	-122	-114	-107	-100	-115
Additional Paid-In Capital	0.2%	322	322	321	319	318	318	315	257	199	198	184	183	179	174	173	170	169	169	168	168	-
Shares Outstanding	1.0%	69.00	68.00	64.00	63.00	60.00	60.00	53.00	60.00	31.00	29.00	22.00	20.00	19.00	19.00	-	-	-	-	-	-	-
Float	-	-	-	-	106	-	-	-	65.00	-	-	-	22.00	-	-	-	42.00	-	-	-	29.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-64.6%	-10,467	-6,359	-7,279	-9,875	-8,197	-6,331	-8,576	-6,176	-7,092	-6,229	-7,241	-7,898	-7,578	-8,924	-6,967	-8,436	-4,673	-6,202	-7,734	-5,061	-4,096
Share Based Compensation	35.5%	723	534	530	606	578	501	569	520	737	540	540	745	718	510	588	589	730	373	371	237	146
Cashflow From Investing	-163.0%	-8,091	12,845	17,982	19,639	8,962	-48,306	-4,850	-	-	-	-	-	-	-5.00	-15.00	-	-	-	-	-	-9.00
Cashflow From Financing	48.1%	-28.00	-54.00	1,510	-7,663	-1,703	652	55,302	55,978	-625	13,741	134	2,753	4,147	637	16,095	-	-	-	-138	63,502	9,849

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TRVI Income Statement

2024-03-31

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 8,804	$ 5,000
General and administrative	3,102	2,563
Total operating expenses	11,906	7,563
Loss from operations	(11,906)	(7,563)
Other income (expense):
Interest income, net	998	1,221
Other (expense) income, net	(1)	165
Interest expense	(1)	(231)
Total other income, net	996	1,155
Loss before income taxes	(10,910)	(6,408)
Income tax benefit	8	7
Net loss	$ (10,902)	$ (6,401)
Basic net loss per common share outstanding	$ (0.11)	$ (0.06)
Diluted net loss per common share outstanding	$ (0.11)	$ (0.06)
Weighted average common shares used in net loss per share attributable to common stockholders, basic	99,517,212	98,610,671
Weighted average common shares used in net loss per share attributable to common stockholders, diluted	99,517,212	98,610,671
Net loss	$ (10,902)	$ (6,401)
Other comprehensive loss:
Net unrealized (losses) gains on available-for-sale marketable securities	(38)	34
Comprehensive loss	$ (10,940)	$ (6,367)

TRVI Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 13,811	$ 32,397
Marketable securities	59,009	50,574
Prepaid expenses	3,225	3,621
Other current assets	721	955
Total current assets	76,766	87,547
Operating lease right-of-use assets	1,084	1,137
Other non-current assets	311	297
Property, equipment and leasehold improvements, net	204	216
Finance lease right-of-use assets	194	206
Total assets	78,559	89,403
Current liabilities:
Accounts payable	2,112	1,809
Accrued expenses	2,842	3,709
Operating lease liabilities	198	184
Finance lease liabilities	124	122
Total current liabilities	5,276	5,824
Operating lease liabilities	949	1,001
Finance lease liabilities		31
Total liabilities	6,225	6,856
Commitments and contingencies (Note 12)
Stockholders’ equity:
Preferred stock: $0.001 par value; 5,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued or outstanding at March 31, 2024 and December 31, 2023.
Common stock: $0.001 par value; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; and 68,960,167 and 68,283,699 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively.	69	68
Additional paid-in capital	322,368	321,642
Accumulated other comprehensive loss	(67)	(29)
Accumulated deficit	(250,036)	(239,134)
Total stockholders’ equity	72,334	82,547
Total liabilities and stockholders’ equity	$ 78,559	$ 89,403

About Trevi Therapeutics Inc

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio for the treatment of serious cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b/3 clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

CEO	Ms. Jennifer L. Good
WEBSITE	trevitherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	30

Trevi Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Trevi Therapeutics Inc? What does TRVI stand for in stocks?

TRVI is the stock ticker symbol of Trevi Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Trevi Therapeutics Inc (TRVI)?

As of Fri May 17 2024, market cap of Trevi Therapeutics Inc is 194.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TRVI stock?

You can check TRVI's fair value in chart for subscribers.

What is the fair value of TRVI stock?

You can check TRVI's fair value in chart for subscribers. The fair value of Trevi Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Trevi Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TRVI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Trevi Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether TRVI is over valued or under valued. Whether Trevi Therapeutics Inc is cheap or expensive depends on the assumptions which impact Trevi Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TRVI.